October Pharma S.A.E (EGX:OCPH)
Egypt · Delayed Price · Currency is EGP 188.51
-2.02 (-1.06%)
At close: Sep 17, 2025
October Pharma S.A.E Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 1,413 | 1,228 | 1,012 | 727.37 | 655.04 | 543.4 | Upgrade | |
Revenue Growth (YoY) | 25.03% | 21.39% | 39.08% | 11.04% | 20.54% | 3.88% | Upgrade |
Cost of Revenue | 813.15 | 704.64 | 515.45 | 375.34 | 331.75 | 291.86 | Upgrade |
Gross Profit | 600.14 | 523.39 | 496.2 | 352.03 | 323.29 | 251.54 | Upgrade |
Selling, General & Admin | 201.24 | 181.27 | 164.4 | 139.53 | 121.93 | 97.71 | Upgrade |
Other Operating Expenses | 17.27 | 18.85 | 18.98 | 10.67 | 3.61 | 1.08 | Upgrade |
Operating Expenses | 223.39 | 202.82 | 189.14 | 152.8 | 127.75 | 106.49 | Upgrade |
Operating Income | 376.74 | 320.57 | 307.06 | 199.23 | 195.54 | 145.04 | Upgrade |
Interest Expense | -145.83 | -130.86 | -62.77 | -27.7 | -30.2 | -31.91 | Upgrade |
Currency Exchange Gain (Loss) | 0.08 | 14.24 | 0.17 | 1.61 | -0.7 | 0.02 | Upgrade |
Other Non Operating Income (Expenses) | -9.8 | - | - | - | - | - | Upgrade |
EBT Excluding Unusual Items | 221.19 | 203.94 | 244.45 | 173.14 | 164.65 | 113.16 | Upgrade |
Gain (Loss) on Sale of Assets | 0.07 | 4.1 | 0.24 | 0.34 | - | 0.05 | Upgrade |
Other Unusual Items | -5.08 | -5.08 | - | - | - | - | Upgrade |
Pretax Income | 216.18 | 202.96 | 244.69 | 173.48 | 164.65 | 113.21 | Upgrade |
Income Tax Expense | 54.12 | 51.12 | 62.56 | 42.74 | 44.85 | 24.95 | Upgrade |
Net Income | 162.06 | 151.84 | 182.13 | 130.75 | 119.79 | 88.26 | Upgrade |
Preferred Dividends & Other Adjustments | 11.6 | 20.57 | 31.73 | 17.02 | - | - | Upgrade |
Net Income to Common | 150.47 | 131.26 | 150.4 | 113.73 | 119.79 | 88.26 | Upgrade |
Net Income Growth | -11.52% | -16.63% | 39.30% | 9.15% | 35.73% | 160.91% | Upgrade |
Shares Outstanding (Basic) | 11 | 12 | 12 | 12 | 12 | 12 | Upgrade |
Shares Outstanding (Diluted) | 11 | 12 | 12 | 12 | 12 | 12 | Upgrade |
EPS (Basic) | 13.25 | 10.94 | 12.53 | 9.48 | 9.98 | 7.35 | Upgrade |
EPS (Diluted) | 13.25 | 10.94 | 12.53 | 9.48 | 9.98 | 7.35 | Upgrade |
EPS Growth | 0.92% | -12.72% | 32.24% | -5.06% | 35.73% | 160.91% | Upgrade |
Free Cash Flow | 309.26 | -9.82 | 117.98 | -185 | 242.43 | 47.65 | Upgrade |
Free Cash Flow Per Share | 27.23 | -0.82 | 9.83 | -15.42 | 20.20 | 3.97 | Upgrade |
Dividend Per Share | - | - | 2.500 | - | - | 1.500 | Upgrade |
Gross Margin | 42.46% | 42.62% | 49.05% | 48.40% | 49.35% | 46.29% | Upgrade |
Operating Margin | 26.66% | 26.10% | 30.35% | 27.39% | 29.85% | 26.69% | Upgrade |
Profit Margin | 10.65% | 10.69% | 14.87% | 15.63% | 18.29% | 16.24% | Upgrade |
Free Cash Flow Margin | 21.88% | -0.80% | 11.66% | -25.43% | 37.01% | 8.77% | Upgrade |
EBITDA | 408.75 | 350.46 | 329.17 | 221.23 | 216.34 | 163.87 | Upgrade |
EBITDA Margin | 28.92% | 28.54% | 32.54% | 30.41% | 33.03% | 30.16% | Upgrade |
D&A For EBITDA | 32 | 29.89 | 22.11 | 22 | 20.8 | 18.82 | Upgrade |
EBIT | 376.74 | 320.57 | 307.06 | 199.23 | 195.54 | 145.04 | Upgrade |
EBIT Margin | 26.66% | 26.10% | 30.35% | 27.39% | 29.85% | 26.69% | Upgrade |
Effective Tax Rate | 25.03% | 25.19% | 25.57% | 24.63% | 27.24% | 22.04% | Upgrade |
Advertising Expenses | - | 5.47 | 4.99 | 6.71 | 5.17 | 5.75 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.